Mirum Pharmaceuticals (MIRM) COO awarded options, RSUs and PSUs in Form 4

Q: What did Mirum Pharmaceuticals (MIRM) disclose in Peter Radovich's latest Form 4?

The filing shows President and COO Peter Radovich received equity awards on January 28, 2026: a stock option for 25,120 shares , 16,280 restricted stock units , and 34,500 performance restricted stock units , all reported as directly owned after the transactions.

Q: How many stock options did Mirum’s President and COO receive according to the Form 4?

Peter Radovich received a stock option for 25,120 shares of Mirum common stock. The option has an exercise price of $100.85 per share and vests 25% one year after January 28, 2026, with the remaining shares vesting in 36 equal monthly installments.

Q: What are the terms of the restricted stock units granted to Peter Radovich at Mirum (MIRM)?

Radovich was granted 16,280 restricted stock units , each representing one Mirum common share. One-third of these RSUs vest on each anniversary of January 28, 2026 , so the award becomes fully vested on the third anniversary of that vesting commencement date.

Q: How do the performance restricted stock units for Mirum’s President vest?

The Form 4 reports 34,500 performance restricted stock units granted earlier, with performance criteria confirmed met on January 28, 2026 . These PSUs vest in two tranches: two-thirds on March 15, 2026 and one-third on March 15, 2027 , subject to those conditions.

Q: Are Peter Radovich’s Mirum (MIRM) equity awards reported as directly or indirectly owned?

All reported awards are listed as directly owned . The Form 4 indicates direct ownership for the 25,120 stock options , 16,280 restricted stock units , and 34,500 performance restricted stock units , with no disclosure of intermediary entities or indirect ownership structures.

Q: What is the vesting schedule of the stock options granted to Mirum’s President and COO?

The 25,120-share stock option vests over four years. One-quarter of the shares vest one year after January 28, 2026 , and the remaining three-quarters vest in 36 equal monthly installments starting from the first anniversary of that vesting commencement date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mirum Pharmaceuticals’ President and COO Peter Radovich reported new equity awards dated January 28, 2026. He received a stock option for 25,120 shares of common stock at an exercise price of $100.85 per share.

He was also granted 16,280 restricted stock units, each representing one share of common stock, vesting in three equal annual installments starting January 28, 2027. In addition, 34,500 performance restricted stock units tied to performance criteria that were determined met on January 28, 2026 will vest as follows: two-thirds on March 15, 2026 and the remaining one-third on March 15, 2027. All awards are reported as directly owned.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Radovich Peter

Role PRESIDENT AND COO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,120	$0.00	--
Grant/Award	Restricted Stock Units	16,280	$0.00	--
Grant/Award	Performance Restricted Stock Units	34,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,120 shares (Direct); Restricted Stock Units — 16,280 shares (Direct); Performance Restricted Stock Units — 34,500 shares (Direct)

Footnotes (1)

1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

Form 4 Insider Transactions: What Each Field Means →

01/30/2026 - 06:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND COO

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$100.85	01/28/2026		A		25,120		⁽¹⁾	01/27/2036	Common Stock	25,120	$0	25,120	D
Restricted Stock Units	⁽²⁾	01/28/2026		A		16,280		⁽³⁾	⁽³⁾	Common Stock	16,280	$0	16,280	D
Performance Restricted Stock Units	⁽²⁾	01/28/2026		A		34,500		⁽⁴⁾	⁽⁴⁾	Common Stock	34,500	$0	34,500	D

Explanation of Responses:

1. 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

4. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Mirum Pharmaceuticals (MIRM) disclose in Peter Radovich's latest Form 4?

The filing shows President and COO Peter Radovich received equity awards on January 28, 2026: a stock option for 25,120 shares, 16,280 restricted stock units, and 34,500 performance restricted stock units, all reported as directly owned after the transactions.

How many stock options did Mirum’s President and COO receive according to the Form 4?

Peter Radovich received a stock option for 25,120 shares of Mirum common stock. The option has an exercise price of $100.85 per share and vests 25% one year after January 28, 2026, with the remaining shares vesting in 36 equal monthly installments.

What are the terms of the restricted stock units granted to Peter Radovich at Mirum (MIRM)?

Radovich was granted 16,280 restricted stock units, each representing one Mirum common share. One-third of these RSUs vest on each anniversary of January 28, 2026, so the award becomes fully vested on the third anniversary of that vesting commencement date.

How do the performance restricted stock units for Mirum’s President vest?

The Form 4 reports 34,500 performance restricted stock units granted earlier, with performance criteria confirmed met on January 28, 2026. These PSUs vest in two tranches: two-thirds on March 15, 2026 and one-third on March 15, 2027, subject to those conditions.

Are Peter Radovich’s Mirum (MIRM) equity awards reported as directly or indirectly owned?

All reported awards are listed as directly owned. The Form 4 indicates direct ownership for the 25,120 stock options, 16,280 restricted stock units, and 34,500 performance restricted stock units, with no disclosure of intermediary entities or indirect ownership structures.

What is the vesting schedule of the stock options granted to Mirum’s President and COO?

The 25,120-share stock option vests over four years. One-quarter of the shares vest one year after January 28, 2026, and the remaining three-quarters vest in 36 equal monthly installments starting from the first anniversary of that vesting commencement date.